Today: 2 July 2026
Browse Category

NASDAQ:IMNM 15 December 2025 - 9 January 2026

Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

Immunome (IMNM) stock drops 5% as biotech slips; investors look to Jan. 14 update

NEW YORK, Jan 5, 2026, 15:54 EST — Regular session Shares of Immunome, Inc. fell 5.3% to $19.72 in late afternoon trading on Monday, underperforming U.S. biotech peers. The SPDR S&P Biotech ETF slid 1.1% and the iShares Nasdaq Biotechnology ETF was off 0.9%. IMNM opened at $20.83 and touched $19.36, with about 1.6 million shares changing hands by 3:54 p.m. EST, according to market data.
5 January 2026
·
Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome (IMNM) Stock Today: Phase 3 RINGSIDE Win, $400M Offering, and Fresh Analyst Targets (Dec. 16, 2025)

Immunome, Inc. is in the spotlight on December 16, 2025, after the company reported positive topline Phase 3 results for its lead desmoid tumor program and then moved to raise significant new capital—two catalysts that can push a biotech stock in opposite directions at the same time. On the one hand: a clear late-stage efficacy win that supports an FDA filing. On the other: a proposed $400 million common stock offering that introduces near-term dilution risk. Reuters+2Immunome Investors+2 Below is a comprehensive, news-driven look at what happened, what analysts are forecasting, and what matters next for IMNM stock as of today.
16 December 2025
··
Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

December 15, 2025 — Immunome, Inc. is having the kind of biotech day that traders circle in red ink: a major clinical trial win, a sharp move in the share price, and a fast-rising debate over what “best-in-class” might be worth if regulators agree. The catalyst is Immunome’s positive topline Phase 3 RINGSIDE results for varegacestat in progressing desmoid tumors—a rare, non-metastatic but often aggressive disease that can cause severe pain and disability. Reuters reported the news pushed the stock up 34.3% in premarket trading Monday. Reuters
15 December 2025

Stock Market Today

  • M-tron Industries (MPTI) edges higher as market slips, outlook mixed ahead of earnings
    July 1, 2026, 8:11 PM EDT. M-tron Industries, Inc. (MPTI) gained 1.61% to $100.75 even as the S&P 500 slipped 0.22%, the Dow lost 0.03%, and the Nasdaq fell 0.66%. Shares had previously jumped 8.27%, outpacing the Construction sector's 5.89% move and dodging the S&P 500's 1.21% loss. EPS for the coming quarter is expected at $0.47, down 11.32% from last year, while revenue is seen rising 11.45% to $14.8 million. For the year, forecasts put EPS at $2.26 on $59.7 million in revenue, a 13.74% earnings drop and 9.71% revenue gain. MPTI trades at a Forward P/E of 43.87, above the industry's 38.44, with a PEG ratio of 1.75 compared to 2.05 for peers. Zacks gives the stock a Rank #5 (Strong Sell), as analysts remain cautious on mixed signals.
Go toTop